Cobimetinib vs Trametinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Melanoma
Shared mechanism: MEK1/2 · full Melanoma pipeline
Cobimetinib
Marketed by Roche and partners
NCT01689519 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 495 participants. Its primary clinical endpoint, progression-free survival, was significantly better with cobimetinib plus vemurafenib than with vemurafenib plus placebo (hazard ratio 0.51, p=0.0001).
Next expected readout: December 2026 · NCT04835805 (registry estimate)
No aligned efficacy figure on record for this race.
Trametinib
Marketed by Novartis and partners
NCT02039947 · Phase 2 · completed
The study was open-label, nonrandomized, and had no comparator arm; all participants received dabrafenib plus trametinib. Although the primary intracranial response result was reported as 45 of 76 participants (59%), the uncontrolled design provides weak evidence for trametinib’s treatment effect.
Next expected readout: February 2027 · NCT04417621 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Melanoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Cobimetinib: registry results are on file for Melanoma, but their comparison mappings are not yet available.
Trametinib: registry results are on file for Melanoma, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cobimetinib's landscape · Trametinib's landscape